Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Prevention |
RCV000721763 | SCV000852898 | uncertain significance | not provided | 2018-08-17 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002493292 | SCV002782768 | uncertain significance | Central core myopathy; Malignant hyperthermia, susceptibility to, 1; Congenital multicore myopathy with external ophthalmoplegia; Congenital myopathy with fiber type disproportion; King Denborough syndrome | 2021-10-09 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003353006 | SCV004077789 | uncertain significance | Inborn genetic diseases | 2023-06-26 | criteria provided, single submitter | clinical testing | The c.9989A>G (p.D3330G) alteration is located in exon 66 (coding exon 66) of the RYR1 gene. This alteration results from an A to G substitution at nucleotide position 9989, causing the aspartic acid (D) at amino acid position 3330 to be replaced by a glycine (G). Based on data from gnomAD, the G allele has an overall frequency of <0.001% (1/248926) total alleles studied. The highest observed frequency was 0.001% (1/111280) of European (non-Finnish) alleles. This amino acid position is highly conserved in available vertebrate species. The in silico prediction for this alteration is inconclusive. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |